Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06594172 | Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy | PHASE2 | NOT YET_RECRUITING | 67 | — | — | Sep 10, 2024 | Jun 30, 2027 | Sep 19, 2024 | - | — |
the proportion of participants who experience cognitive impairments after radiation therapy
| Arm | Type | Description |
|---|---|---|
| MPR | EXPERIMENTAL | combined Memantine and Pioglitazone with radiation therapy |
| Name | Type | Description |
|---|---|---|
| Memantine Oral Tablet | DRUG | Oral administration of Memantine Tablets (10mg/tablet): Week 1: 5mg in the morning. Week 2: 5mg twice daily. Week 3: 10mg in the morning, 5mg in the evening. Weeks 4-24: 10mg twice daily. |
| Pioglitazone 15mg | DRUG | Simultaneous oral administration of Pioglitazone Tablets (15mg/tablet): Weeks 1-24: 30mg once daily. |
| Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) | RADIATION | Based on the RTOG 0933 protocol, hippocampal and perihippocampal regions are delineated, and hippocampal dose constraints are applied. The radiation dose to the perihippocampal region is determined based on the size, number, and volume of brain metastases (whole-brain radiation therapy: DT 30Gy/10F, weeks 1-2; with a simultaneous boost to the pathological local area if necessary, 10-20Gy). |
Inclusion Criteria: * Recursive Partitioning Analysis (RPA), Class I \~ Class II * Karnofsky Performance Status of ≥70 * The primary tumor must be pathologically confirmed. For newly diagnosed brain metastases, the number of metastases is not limited, but the brain metastases could not have been wi...